Kronos Bio, Inc. (KRON) Tops Q2 EPS by 9c

Kronos Bio, Inc. (NASDAQ: KRON) reported Q2 EPS of ($0.27), $0.09 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $2.69 million versus the consensus estimate of $1.53 million.

For earnings history and earnings-related data on Kronos Bio, Inc. (KRON) click here.

You May Also Be Interested In

• Lear Corp. (LEA) Tops Q2 EPS by 36c ; Offers Guidance
• Portland General Electric (POR) Misses Q2 EPS by 10c ; Offers Guidance
• Eaton (ETN) Tops Q2 EPS by 8c, Beats on Revenue; Offers Q3 Guidance